
Tagrisso Approved, but Can Patients With EGFR-Mutant NSCLC Afford It?
The drug is estimated to cost close to $13,000 per month.
Last week, AstraZeneca’s epidermal growth factor receptor (EGFR) inhibitor, osimertinib (Tagrisso), was
Having specifically developed the drug for a subset of NSCLC patients, AstraZeneca collaborated with Roche Diagnostics to develop a companion diagnostic, the cobas EGFR Mutation Test v2, which detects EGFR mutations in NSCLC tissue samples.
While oncologists such as Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, have
According to a company
While previous estimates from AstraZeneca projected a $3 billion annual market for the drug, the news of Clovis Oncology’s competitor product hitting a snag in their FDA review could further open up the market for AstraZeneca. CO-1686 or rociletinib, which has shown
Meanwhile, Diplomat Pharmacy, the largest independent specialty pharmacy in the country, has
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.